Jump to content

Neil Blumberg

Members
  • Posts

    215
  • Joined

  • Last visited

  • Days Won

    90
  • Country

    United States

Everything posted by Neil Blumberg

  1. My condolences to her family, colleagues and friends.
  2. I don't think the AABB comments are evidence based. Washing with 37 degree saline is extremely unlikely to cause false negatives with clinically significant antibodies, and I'm unaware of any evidence that this is so. Any such antibody would be very low affinity to be washed away by saline at any temperature, and unlikely to have in vivo/clinical significance. As argued persuasively above by Malcolm Needs, anything that doesn't react at 30 degrees or above in typical serologic testing isn't going to cause clinical problems. Patients are neither at 30 degrees nor centrifuged :). Our serologic techniques are overly sensitive, in general, for clinically insignificant agglutinins. No need for cold panels ever, with rare exception, and more for intellectual curiosity than clinical decision making. Perhaps a mini-cold screen someetimes just to confirm you are indeed detecting a weak cold agglutinin in 37 degree testing, which disappears with prewarm technique. Like Malcolm, I've never seen a patient with an hemolytic reaction due to an antibody that disappears with prewarming, in close to 50 years of clinical practice. I know there are in vitro examples of clinically significant antibodies that weaken or disappear with prewarm, but I've never seen any clinical consequences.
  3. In emergencies, we always accept verbal orders for transfusion. These should be followed up by a request documented in our electronic medical record, but that's after the fact. If you have a paper system, then the followup order is documented that way. There is a regulatory/accreditation requirement, which I consider bureaucratic, obstructive and useless, that these emergency requests require a signed release from the ordering practitioner, if the transfusion is not fully tested for the recipient.
  4. Agree that a urine specimen isn't indicated for an allergic reaction, so no worries.
  5. Here's one paper that involves extended cold storage of room temperature platelets. They actually seemed more functional. Xu F, Gelderman MP, Farrell J, Vostal JG. Temperature cycling improves in vivo recovery of cold-stored human platelets in a mouse model of transfusion. Transfusion. 2013 Jun;53(6):1178-86. doi: 10.1111/j.1537-2995.2012.03896.x. Epub 2012 Sep 24. PMID: 22998069. Background: Platelet (PLT) storage at room temperature (RT) is limited to 5 days to prevent growth of bacteria, if present, to high levels. Storage in cold temperatures would reduce bacterial proliferation, but cold-exposed PLTs are rapidly cleared from circulation by the hepatic Ashwell-Morell (AM) receptor, which recognizes PLT surface carbohydrates terminated by β-galactose. We cycled storage temperature between 4 and 37°C to preserve PLT function and reduce bacterial growth. Study design and methods: Temperature-cycled (TC) human PLTs were stored at 4°C for 12 hours and then incubated at 37°C for 30 minutes before returning back to cold storage. PLTs stored at RT or at 4°C (COLD) or TC for 2, 5, and 7 days were infused into SCID mice and the in vivo recovery was determined at 5, 20, and 60 minutes after transfusion. Results: PLTs stored for 2 days in COLD had significantly lower in vivo recoveries than RT PLTs. TC PLTs had improved recoveries over COLD and comparable to RT PLTs. After 5- and 7-day storage, TC PLTs had better recoveries than RT and COLD PLTs. PLT surface β-galactose was increased significantly for both COLD and TC PLTs compared to RT. Blocking of the AM receptor by asialofetuin increased COLD but not TC PLT recovery. Conclusion: TC cold storage may be an effective method to store PLTs without loss of in vivo recovery. The increased β-galactose exposure in TC PLTs suggests that mechanisms in addition to AM receptors may mediate clearance of cold-stored PLTs.
  6. Short periods of time (<12 to 24 hours say) at refrigerator temperatures have no known deleterious effect on platelet transfusion efficacy, so I would use them as I would use any platelet component stored at room temperature. I routinely approve this at my own institution when this happens.
  7. The fact is that we have little to no evidence that platelet transfusion of any sort will mitigate post-pump bleeding. This is expert opinion only that has driven this practice. What we have learned in the last few years is that platelet transfusion as currently practiced (ignoring ABO for one thing) actually increases bleeding and mortality in some clinical settings. I'd rather have some oozing than be transfused with platelets empirically, both as a patient and a hematologist. With life threatening bleeding and abnormal platelet function as measured by a closure time or TEG/ROTEM, platelet transfusion makes sense and has some data driven support. Oozing, no data whatever.
  8. Sounds like total rubbish from both a clinical and scientific viewpoint. Another instance how the administrative/legal model of reality is undermining civilization :).
  9. I should have added that I recognize that some cardiac surgeons transfuse platelets routinely post-bypass in the hope of reducing bleeding. I suggest this is a traditional practice without the slightest shred of evidence for benefit. Purely guesswork and expert opinion, for which there is now evidence of harm. So whether you give cold or room temp platelets probably doesn't matter as (1) there is likely no benefit to either approach, and (2) there is likely equivalent harm either way. So my short answer is it doesn't matter, but that platelet transfusion to non-bleeding surgical patients likely doesn't help, and may increase the risk of thrombosis, inflammation and reduced host defenses against post-operative infection.
  10. Why are we transfusing platelets to patients who aren’t bleeding? More likely to harm them than help them in my view.
  11. I agree with the procedures above. But these are basic urgent communications required of any clinical service, and I wouldn't characterize them as critical values, which are emergencies. Perhaps it's just semantics :).
  12. We have no critical values in the Blood Bank and we have a cancer center that sees thousands of patients per month. And it is my recommendation that critical values be restricted to truly life threatening conditions that require treatment within minutes to hours (e.g., very high or low potassium). I would most definitely NOT have critical values for things like creatinine/BUN, liver function tests, MCV, white count, etc. Provides no clinically actionable information acutely, and wastes a lot of time in the lab and amongst practitioners.
  13. I'd also add that none of the cell washers are FDA approved for washing platelets. We've been washing platelets on the 2991 for about 40 years :). I believe there may be a paper on using the ACP-215 to wash platelets but as yet we do not have any hands on experience. We have developed a manual method of platelet washing using a Sorvall centrifuge. If your volume isn't too high, you might consider a manual wash method. It takes a bit longer, but actually has higher recoveries (>90% vs. about 80-85% with the 2991). Folks will tell you that washed platelets don't work clinically and the count increment is Washed Tx Leukemia.pdfWashed Tx Leukemia.pdflower. The increment is indeed lower, but if you employ platelets that aren't ABO incompatible with the recipient and remove the supernatant, the clinical results are actually better than the clueless advice to give ABO major incompatible platelets routinely (e.g., group A to group O recipients). The PLADO study had a bleeding rate using this abominable practice of about 70%. Our bleeding rate avoiding infusion of ABO incompatible antigen or antibody is 5%, with or without washing. A fourteen fold difference. So by all means give washed platelets to patients with severe or recurrent reactions, or avoid infusion of ABO incompatible plasma, and, if you believe our randomized trial data, to improve the survival of younger patients with acute myeloid leukemia. References attached if anyone is interestedWashing AML Greener_et_al-2017-American_Journal_of_Hematology.pdf. Washing Review IJCTM-101401-the-clinical-benefit-of-washing-red-blood-cells-before-transfusion.pdf Washing AML Greener Am J Hemat AML Washing Supplementary Figures and Tables.pdf Jill's washing paper.pdf Plt Washing Vo.pdf
  14. There is no regulatory nor clinical reason not to wash AS-3 units on the Haemonetics device. Just validate it for red cell recovery and hemolysis, comparing AS-3 with five AS-1, CPD-A1 or other units you can obtain from another blood center, if this makes you feel more secure. We wouldn't and won't bother to do so. The results will likely be identical. There is no material difference in red cell preservation issues with the various additive solutions and certainly no evidence of difference in clinical outcomes.
  15. This is why all transfusion services need experienced/trained physicians. It's a clinical decision weighing the risks of not transfusing urgently vs. the risks of alloimmunization. And the risks of not having Rh negative red cells for patients where such products provide important safety (girls and women <40-50; patients with anti-D). Obviously the issues in alloimmunizing a male patient, particularly an older patient, are very different from a woman or girl with the potential for future pregnancy. If not terrifically urgent, requires a discussion between the practitioner responsible for the patient and the transfusion service physician. I've certainly made decisions independently and only informed the patient's physician after the fact, when the maintenance of Rh negative red cell supply has been a priority. Hard to write a procedure that covers all possibilities, so one would have to be broadly written, and probably kept it short on details, since these are so variable.
  16. I would like to see studies as to why transfusion services continue to provide ABO non-identical transfusions when they have ABO identical components in stock. ABO mismatched red cells (so-called universal donor group O red cells), platelets and plasma (so-called universal donor AB plasma) have all been associated in randomized trials (platelets) and observational studies (red cells and plasma) with increased mortality, bleeding and other dire complications. Why has an entire specialty failed to take notice of data that contradict long standing dogma? What can be done to improve this performance and reduce suffering, morbidity and mortality amongst our patients? This is particularly important because ABO non-identical platelets may actually make hemostasis worse, and thus no transfusion is likely better than an ABO non-identical platelet transfusion, as one example.
  17. Not in a blood collection center, so no policy. But scientifically there is no rationale for donor deferment. The vaccines are not live/attenuated but rather just protein with no potentially infectious material of concern to recipients. The virus, in any case, should only infect respiratory mucosa and thus would represent minimal to no risk to recipients even if present in donor blood (similar to coronavirus and influenza).
  18. Our Red Cross just informed us that it will discontinue providing CPDA-1 rbc. We primarily used it to provide volume reduced red cells to pediatric patients under 3 years of age. We will volume reduce AS-1 or AS-3 by centrifugation or washing (Terumo 2991) instead. Probably unnecessary for most patients, but this is a long standing practice here, and it doesn't seem worthwhile trying to adjust pediatric practice in this regard. Most patients do not need the additional volume provided by the anticoagulant-preservative in AS-1, etc., and avoiding unnecessary volume is a reasonable goal in many patients. There is no inherent virtue to CPDA-1 vs. AS-1 and similar solutions, and rbc preservation is slightly better in AS-1/AS-3 by in vitro metrics. There is absolutely no factual basis for using CPD-A1 in preference to AS-1, etc. in pediatrics. Purely expert opinion and probably unduly conservative. I've attached a nice presentation by Dr. Saifee at the University of Washington, who createdAdditive solution AS-1 in Children Univ. Washington presentation Dec 2021.pptx it to educate her colleagues about using AS-1 instead of CPDA-1. Additive solution AS-1 in Children Univ. Washington presentation Dec 2021.pptx Pediatric RBC White Paper - November 2021.pdf
  19. Peter was always helpful, gracious and supportive of everyone in the field. He made great contributions, not least of which was his definitive book Applied Blood Group Serology, which was recently reprinted. A fabulous reference for the ages. Doubt it will ever be replaced or exceeded. Hail and farewell.
  20. While it is infrequently referenced, universal leukoreduction is one strategy for minimizing pulmonary and cardiovascular adverse responses to transfusion (see attached). When we instituted it in 2000 our rate of TRALI decreased by 80+ % and TACO decreased by 50%. Probably mechanism is that white cells, DNA, histones and neutrophil extracellular traps (NETs) cause acute lung injury and inflammation when infused (good animal model data exist). Thus the failure to implement universal leukoreduction in the USA during the last 23-25 years was a terrible and tragic mistake, and this fatal error persists to this day. ULR TRALI TACO PMC version.pdf
  21. Larry Petz died about a year ago. He had completed a transition to working on cellular therapies in his later old age. Here's his obituary. He had a long and very productive life. https://obituaries.neptunesociety.com/obituaries/sherman-oaks-ca/lawrence-petz-10780477
  22. We send cards to physicians (for their patients, if they like) because it is our responsibility to patients, not because it works well. If anyone has better ideas, please share them. Obviously a national database would be best. Doing absolutely nothing is not an option from our standpoint.
  23. Another thing to try to increase sensitivity (other than PEG or other enhancement) is to increase the serum/cell ratio in the screen/indirect antiglobulin test. If there is no reactivity with enhancement, enzyme treated rbc (agree with Malcolm's caveat that some antigens will be destroyed) and increased serum/cell, one can be more confident there is nothing detectable pre-transfusion. Some consolation at least ...
  24. One additional approach would be to increase the sensitivity of the antibody screen by your preferred method (e.g., PEG, ± using enzyme treated red cells). Obviously increases the possibility of detecting pan-reactivity/false positive tests.
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.